A multi-center, phase 2, open label study of safety and efficacy of oral recombinant human lactoferrin (rhLF) monotherapy in patients with advanced renal cell carcinoma (RCC), who have failed at least one regimen of systemic therapy for RCC
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2008
At a glance
- Drugs Recombinant lactoferrin (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 08 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 04 Oct 2005 New trial record.